Background: Metastatic breast cancer is a burden on healthcare worldwide. Despite the progress made in early diagnosis and adjuvant treatment of breast cancer again about 30% of patients develop metastases in the course of their disease. Also, there is a percentage of patients where the disease presents in the metastatic stage.

Real-world data may provide valuable information on the effectiveness and safety of medicines, which is particularly relevant for clinicians, patients, and third-party payers. Materials and methods: We have collected data from 63 patients at University Hospital Centre “Mother Teresa”, Tirana, Albania, receiving Palbociclib from June 2016 until October 2019. Patients aged≥18 years, diagnosed with ABC and exposed to Palbociclib plus Fulvestrant. Patients were followed-up until death.

RESULTS; A total of 63 patients were included. The median age was 66 years (range 28–78) and 99.05% were female. The Median follow-up time was 26.42 months…

Conclusion: Palbociclib plus Lulvestrant seems an effective treatment for ABC in a real-world context. Compared to registration studies, as in the world practice, these medications are first-line treatments in Albania as well, constituting a significant achievement in the fight against breast cancer.

Keywords: breast cancer, Palbociclib, Fulvestrant, Real-world data, oncology services